FDA Approves Adjuvant Imatinib

On December 19, 2008 the US FDA announced approval of the use of imatinib (Gleevec) as adjuvant treatment (prescribed after complete surgical resection) to prevent recurrence of GIST. Below is a link to the brief announcement. More details should emerge soon.